Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT02960737
Recruiting Not applicable

Dysphagia Evaluation After Stroke- Effect Oral Neuromuscular Training on Swallowing Dysfunction

NCT02960737 · tracked via the Priya Life Science Sweden tracker
Sponsor
Umeå University
Phase
Not applicable
Started
2022-12-01
Last updated
2026-05-08

Condition(s) studied

DysphagiaStroke

Investigational drug(s) / intervention(s)

Oral neuromuscular training using an oral device

Oral neuromuscular training using an oral device: The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.

Study summary

The aim of this study is to investigate the effect of a specific rehabilitation program with an oral device used in stroke patients with persistent oral-and pharyngeal dysphagia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Persistent dysphagia 12(±3) weeks after STROKE. Exclusion Criteria: * Stroke patients with neurologic or psychiatric disorders or other diseases/conditions that can affect swallowing function. * Unable to collaborate due to other serious diseases and/or to affected general condition.

Primary outcome measure(s)

  • Swallowing Function — At start compared with at end of treatment (after 3 months)
    Change in swallowing function measured by the Dysphagia Outcome Severity Scale (DOSS) using Fiberoptic endoscopic evaluation of swallowing (FEES)

Trial sites (1)

FacilityCityRegionStatus
University Hospital of Umeå Umeå Sweden Recruiting

More Umeå University trials in Sweden

The eHealth Diabetes Remission Trial Recruiting
Clinical Effectiveness of TARA Compared to Standard Treatment for Adolescents and Young Adults With Depression Active, not recruiting
Prognostic Factors in Periampullary Tumors and Cysts Recruiting
A Comparative Study of Stem and Cup Fixation and Polyethylene Wear Active, not recruiting
Abdominal Rectus Diastasis Microscopy and Rehabilitation (AMIRE) Active, not recruiting

Other trials for the same condition

Stroke Rehabilitation Using Extended Reality. Starting soon
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes Recruiting
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation Recruiting
Internet Delivered Cognitive Rehabilitation for Mild Cognitive Impairments Enrolling by invitation
Evaluation of the Ronnie Gardiner Method in Individuals With Stroke in Late Phase of Recovery Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02960737 on ClinicalTrials.gov ↗ ← All trials in Sweden